|Bid||0.00 x 1200|
|Ask||0.00 x 2900|
|Day's Range||63.07 - 63.82|
|52 Week Range||61.73 - 76.56|
|Beta (5Y Monthly)||0.17|
|PE Ratio (TTM)||33.60|
|Forward Dividend & Yield||1.45 (2.28%)|
|Ex-Dividend Date||Aug 10, 2023|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for AZN
The Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week. The officials on Tuesday met with representatives of Sanofi , AstraZeneca and Thermo Fisher "and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market," the White House said in a statement.
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.